White Paper: Raising Capital for Healthcare Companies Without a Bank
Yes, a healthcare company can raise capital without an investment bank, as long as the owner does the banker's five jobs: price the business, pick the capital layer, build the investor list, produce the materials and negotiate the terms. Three rules do most of the work. Price off private control deals, not public comps. Start with physicians and family offices that already know healthcare. On any sale of existing shares, plan for about a tenth of the price to sit in escrow. The median was 11.1% on 2025 deals without RWI, per SRS Acquiom.
This paper gives the 2026 data for each job, worked examples and a 13-week plan.
Data as of November 20, 2026. Observed data tables report a named source, its population and its period. Model tables are hypothetical. Their inputs are our assumptions and the arithmetic is ours. They are not market quotes. Every derived figure is listed with its inputs at the end of the paper.
Executive summary: 5 numbers that set the terms of a 2026 healthcare raise
- 1,029 PE healthcare deals in 2025, 664 of them add-ons. Of the 1,029 PE-backed healthcare deals tracked in PESP's 2025 in Review (PitchBook and LevinPro HC data), 151 were buyouts, 664 add-ons and 214 growth investments. PESP says its count is likely an underestimate. Growth investments are the closest match to a minority raise. By our arithmetic they made up 20.8% of the total.
- 5.1x versus 12.9x EBITDA. In Axia Growth's closed healthcare sales data (as of October 28, 2026), the median was 5.1x for the 13 sales with $2 million to $3 million of EBITDA and 12.9x for the 17 sales at $10 million and up. Both bands use the same EBITDA basis.
- 9.6x EBITDA. Across Buckhead FMV's 187 U.S. healthcare services control transactions announced January 2023 through October 2026, the median was 9.6x EBITDA (68 deals with positive EBITDA) and 0.88x revenue. Buckhead excludes minority stakes, so this is a control benchmark.
- 11.1% to 14.7% of value held back. SRS Acquiom's 2026 Deal Terms for M&A Escrows reports that total escrow on 2025 deals without RWI had a median of 11.1% of transaction value and an average of 14.7%.
- 2.5% hospital operating margin. Kaufman Hall's Q3 2026 release (October 13, 2026) puts the year-to-date hospital operating margin, including allocations, at 2.5% through August 2026, with nearly 43% of hospitals operating at a loss. Divestitures made up nearly one-third of the 16 hospital deals announced in Q3 2026. That makes systems more likely sellers of outpatient assets than funders of an outside group.
1. Choose the capital type first: the healthcare capital stack
An owner who starts by calling investors usually ends up with whatever structure the first investor proposes. Decide first what the money is for. Then pick the layer that funds that use and gives up the least control.
Order reflects typical priority in a default or sale; actual terms depend on the documents.
Text version
- Senior secured debt (bank, SBA, unitranche): First claim on assets and cash flow; covenants; lowest cost; no ownership
- Asset-based and receivables lending: Borrowing base tied to accounts receivable or equipment; works for revenue-cycle-heavy businesses
- Subordinated or mezzanine debt: Behind senior debt; higher coupon, often warrants; limited control rights
- Preferred equity: Priority on distributions and exit proceeds; negotiated board and consent rights
- Common equity (owners, physicians, sponsors, family offices): Last in line, all of the upside; carries control through the board
- Rollover and management equity: Sellers and physicians who stay invested; value depends on the second sale
HealthcareInvestmentBanking.com
| Layer | Funds | Control given up | What the investor gets | Fits |
|---|---|---|---|---|
| Senior debt (bank, SBA) | Equipment, real estate, working capital | None beyond covenants | Interest, collateral, personal guarantee | Stable EBITDA, hard assets |
| Private credit, unitranche | Acquisitions, dividend recaps | Covenants, sometimes a board observer | Higher coupon, fees, tight covenants | Larger, steady EBITDA |
| Seller note | Buying out a partner or a practice | None | Deferred, subordinated payment | Internal successions, tuck-ins |
| Physician syndication | De novo sites, ASC equity | Minority stake under the operating agreement | Distributions, local ownership | ASCs, imaging, multi-site groups (referral rules in Section 7) |
| Family office direct minority | Growth, partner buyouts, MSO build | Board seat, protective provisions | Patient equity, flexible hold period | Profitable groups that want to stay independent |
| PE growth equity | Platform expansion | Minority stake with heavy vetoes | Preferred return, liquidation preference | Fast-growing services and health IT |
| Control recap (PE platform) | Founder liquidity plus growth | Majority | Control. The founder gets a second exit through rollover | Owners ready to give up control |
Three rules decide most choices.
- Debt is cheaper than equity only while cash flow covers it. PitchBook data reported in Sikich's Q3 2026 update puts 2025 entry leverage on PE-backed healthcare services buyouts at 5.2x EBITDA. Those targets had a median implied EBITDA of roughly $33 million and a sponsor behind them. For a founder-owned group, 5.2x is an outer limit, not a target.
- Know the size limits on cheap debt. The SBA's 7(a) program, its main small business loan program, sets a maximum loan size that can change. Confirm the current limit with your lender before counting on one SBA loan to fund the raise.
- Every step down the stack costs more governance for each dollar raised.
Model, not a market quote: debt versus minority equity. A hypothetical three-site dermatology group has $3.2 million of adjusted EBITDA and $4.0 million of existing net debt. It needs $6.0 million. Our arithmetic. The debt row assumes the full $6.0M is borrowed and added to the existing $4.0M, and that all $10.0M carries an assumed 9% all-in rate. The equity row assumes $6.0M gross with no fees deducted.
| Route | Amount raised | Leverage after the raise | What the owner gives | What the owner keeps |
|---|---|---|---|---|
| New senior debt | $6.0M borrowed | New debt alone 1.9x EBITDA. Total net debt $4.0M plus $6.0M equals $10.0M, or 3.1x | Covenants, guarantee, about $0.9M a year of interest | 100% of the equity |
| Minority equity at $21.6M pre-money (Section 2) | $6.0M of new shares | Unchanged at $4.0M, or 1.3x | 21.7% of the equity, a board seat, protective provisions | 78.3% of the equity, no new debt service |
Interest alone on $10.0M at 9% is $0.9M a year, or 28% of EBITDA, before any principal. The debt route keeps all the equity but more than doubles the fixed claim on cash flow. The equity route leaves cash flow alone and gives up a share of all future value. If you are confident in next year's EBITDA, borrow. If you are not, sell the equity.
Size the raise against each layer in the Capital Raise Sizing Calculator before any investor conversation.
2. Price the round from private-deal data, not public comps
Public multiples set expectations that private buyers will not meet.
Observed data: U.S. public companies, January 2026. Source: Aswath Damodaran, NYU Stern, EV/EBITDA by sector and his separate Price and EV to Sales file. The two files aggregate differently, so do not divide one by the other to infer a margin.
| Public sector (US, January 2026) | EV/EBITDA | EV/Sales |
|---|---|---|
| Healthcare Products (204 firms) | 19.78x | 4.76x |
| Healthcare Support Services (104 firms) | 11.17x | 0.46x |
| Hospitals/Healthcare Facilities (31 firms) | 8.86x | 1.69x |
Public companies are liquid, diversified and large. A private practice is none of those, so it prices lower. The three private sources below each cover a different population and period. Compare figures within a table, not across tables.
Observed data: Axia Growth, closed healthcare small-business sales by size band, as of October 28, 2026. Source: Axia Growth, the healthcare subset of its 4,554 closed small-business sales over $500K. Figures are medians and the middle half (25th to 75th percentile) of sale price to earnings. Bands below $2 million use seller's discretionary earnings (SDE), which adds back owner pay, so SDE multiples run lower than EBITDA multiples on the same business.
| Size band | Sales (n) | Median multiple | Middle half | Basis |
|---|---|---|---|---|
| Under $500K SDE | 182 | 3.4x | 2.7x to 4.2x | SDE |
| $500K to $1M SDE | 42 | 3.4x | 2.5x to 4.4x | SDE |
| $1M to $2M SDE | 22 | 3.3x | 2.7x to 7.5x | SDE |
| $2M to $3M EBITDA | 13 | 5.1x | 3.1x to 10.9x | EBITDA |
| $3M to $5M EBITDA | Not published | Not published | Not published | |
| $5M to $10M EBITDA | 14 | 8.8x | 3.4x to 10.7x | EBITDA |
| $10M+ EBITDA | 17 | 12.9x | 9.4x to 18.5x | EBITDA |
Bands under $2M use seller discretionary earnings (SDE); larger bands use EBITDA.
Chart data
| Under $500K SDE (n=182) | 3.4 |
|---|---|
| $500K to $1M SDE (n=42) | 3.4 |
| $1M to $2M SDE (n=22) | 3.3 |
| $2M to $3M EBITDA (n=13) | 5.1 |
| $5M to $10M EBITDA (n=14) | 8.8 |
| $10M+ EBITDA (n=17) | 12.9 |
Source: Axia Growth, Physician Practice Management sales dataset
Samples above $2 million are small and the ranges are wide. Read the medians as direction. Axia publishes no $3 million to $5 million band, so the worked example below uses Sikich's range for that size.
Observed data: Sikich indicative EV/EBITDA ranges, Q3 2026. Source: Sikich Q3 2026 US healthcare M&A update. These are ranges Sikich publishes as indicative pricing, not medians of a stated deal set. Use them as a starting band for negotiation.
| Sub-sector | Size or type | Indicative EV/EBITDA, as published by Sikich |
|---|---|---|
| Physician practices | Under $1M EBITDA | 5 to 7x |
| Physician practices | $1M to $3M EBITDA | 7 to 9x |
| Physician practices | $3M to $5M EBITDA | 9 to 11x |
| Physician practices | Above $5M EBITDA | 11 to 13x |
| Physician practices | Platform versus add-on, same specialty | Platforms 4 to 8 turns higher |
| ASCs | Single-specialty / multispecialty / regional operators | 5 to 8x / 6 to 10x / 11 to 17x |
| ASCs | 2025 median | 7.9x, the highest in at least eight years |
| Dental (DSOs) | Platforms / add-ons / practices | 9 to 11x / 5 to 8x / 5 to 9x |
| Home health and hospice | Enhabit take-private / small agencies | 10.2x / mid-single digits |
| Urgent care | Under $10M revenue / $10M to $50M revenue | 3 to 7x / 6 to 11x |
| Hospitals, public comps as of June 30, 2026 | HCA / Community Health / Ardent | 8.5x / 7.5x / 6.1x |
Observed data: Buckhead FMV, U.S. healthcare services control transactions announced January 1, 2023 through October 31, 2026. Source: Buckhead FMV. The set is 187 deals with a disclosed or court-approved price and primary-source target financials. Minority and physician-syndication stakes are excluded. Buckhead shows EV/EBITDA only where EBITDA was positive. "Not published" means Buckhead gives no figure for that cell.
| Cut | Median EV/EBITDA | Median EV/revenue |
|---|---|---|
| All 187 deals (EBITDA median on 68 deals with positive EBITDA) | 9.6x | 0.88x |
| Excluding bankruptcy and other distressed sales | 10.1x | 0.98x |
| By year: 2023 / 2024 / 2025 / 2026 through October 31 | 11.4x / 9.7x / 6.5x / 9.1x | Not published |
| Deals under $10M | 2.8x | 0.27x |
| Deals above $200M | 11.2x | 1.34x |
| Ambulatory surgery centers | 12.4x | 1.24x |
| Outsourced services | 11.6x | 2.8x |
| Hospitals | 9.5x | 0.41x |
| Primary care practices | Not published | 0.11x |
| 22 distressed sales with reported revenue | Not published | 0.15x |
Buckhead notes that large and public-company deals disclose EBITDA far more often than small private ones, which pulls its EBITDA medians toward bigger transactions. That explains much of the gap between its 12.4x ASC median and Sikich's 5 to 8x single-specialty range. The 0.11x primary care figure reflects hospital purchases of individual practices that Buckhead says price near equipment and records value.
Observed data: PitchBook market-level medians. Source: PitchBook data reported in Sikich's Q3 2026 update. The 2026 figure is year to date as of that Q3 2026 update.
| Measure | 2024 | 2025 | 2026 YTD |
|---|---|---|---|
| Median healthcare M&A EV/EBITDA | 14.5x | 13x | 11.6x |
| Median EV/EBITDA, PE-backed healthcare services buyouts | 13.5x | 13.6x | Not published |
| Implied EBITDA of the median PE-backed target | Not published | Roughly $33M | Not published |
These medians describe targets with roughly ten times the EBITDA of the $3.2 million group in our example. They show where a platform ends up, not what a $3 million practice should expect today.
Four pricing rules follow.
- Scale is the price. Buckhead calls scale the largest single driver in its data, with medians running from 2.8x on deals under $10 million to 11.2x above $200 million. A raise that moves the company into the next size band adds more value than one that only funds operations.
- Platforms earn a premium. Sikich puts it at four to eight turns over add-on practices in the same specialty. An investor who prices you as an add-on keeps that spread.
- Strip out distress before you compare. Buckhead's median rises from 9.6x to 10.1x without distressed sales. Buckhead attributes its 6.5x 2025 median to a smaller, more mid-market deal mix, not a broad repricing.
- Every benchmark above is a control price. A minority investor gets no control, no say over the exit date and no power to replace management. It pays a lower multiple or recovers the difference through liquidation preferences, preferred returns and vetoes. None of these datasets publishes a standard minority discount. Put the discount on the table as an explicit number.
Model, not a market quote: pricing a minority round. The same hypothetical group has $3.2 million of adjusted EBITDA and $4.0 million of net debt. It raises $6.0 million of new money. All figures are gross, before transaction fees, option pools or any other dilution. Two inputs are our assumptions. The 9.5x control reference is a point we chose inside Sikich's 9 to 11x band for practices with $3 million to $5 million of EBITDA. The 8.0x minority multiple is 15.8% below that reference.
| Step | Calculation | Result |
|---|---|---|
| Control reference value (assumed 9.5x) | $3.2M x 9.5 | $30.4M enterprise value |
| Minority enterprise value (assumed 8.0x) | $3.2M x 8.0 | $25.6M |
| Less net debt | $25.6M minus $4.0M | $21.6M pre-money equity |
| Add new capital | $21.6M plus $6.0M | $27.6M post-money equity |
| Investor ownership | $6.0M divided by $27.6M | 21.7% |
| Same raise at the control reference | $6.0M divided by ($26.4M plus $6.0M) | 18.5% |
On these assumptions the minority discount costs the founder 3.2 points of ownership.
Model, not a market quote: what each turn of multiple costs the founder. Same group, same $6.0M gross raise, no fees. Pre-money equity equals $3.2M times the multiple, minus $4.0M of net debt. Investor ownership equals $6.0M divided by pre-money plus $6.0M.
| Multiple (input) | Discount to 9.5x reference | Pre-money equity | Investor ownership |
|---|---|---|---|
| 9.5x | 0% | $26.4M | 18.5% |
| 9.0x | 5.3% | $24.8M | 19.5% |
| 8.5x | 10.5% | $23.2M | 20.5% |
| 8.0x | 15.8% | $21.6M | 21.7% |
| 7.5x | 21.1% | $20.0M | 23.1% |
| 7.0x | 26.3% | $18.4M | 24.6% |
| 6.5x | 31.6% | $16.8M | 26.3% |
Suppose an investor argues for 6.5x because two of the three sites are less than three years old. Going from 8.0x to 6.5x costs the founder another 4.6 points. Site-level P&Ls and a documented EBITDA bridge are what defend the higher number.
Test your range against the Healthcare Valuation Multiples guide before it goes into a deck.
3. Map who is writing checks: where 1,029 PE healthcare deals went in 2025
Capital keeps coming to the sector because spending keeps growing. Per the CMS National Health Expenditure fact sheet, US health spending grew 7.2% to $5.3 trillion in 2024, 18.0% of GDP. Physician and clinical services spending grew 8.1% to $1,109.7 billion. CMS projects physician and clinical services spending to grow 5.5% a year on average from 2025 to 2034.
Observed data: PE healthcare deals, 2025. Source: PESP's 2025 in Review, built from PitchBook and LevinPro HC data. PESP tracked 420 platform companies and 708 investment firms, and says its count is likely an underestimate. By our arithmetic, add-ons were 64.5% of the 1,029 deals, buyouts 14.7% and growth investments 20.8%.
| Subsector (PESP, 2025) | PE deals | What it means for a raise |
|---|---|---|
| Health IT | 151 | The most active subsector. Growth equity and minority rounds are part of the mix |
| Dental care | 149 | 95% were add-ons by PE-owned platforms. Independent practices mostly get bought, not funded |
| Outpatient care | 148 | 119 add-ons. Dermatology 24, eye care 22, oncology 9 |
| Medtech | 117 | Product risk. Investors underwrite regulatory milestones |
| Behavioral health | 56 | Fewer deals. Compliance diligence runs deeper |
The outpatient breakdown comes from Becker's ASC Review's summary of PESP 2025 outpatient data. By our arithmetic, 119 of 148 outpatient deals, or 80.4%, were add-ons. PESP also reports that ten of the 18 platform companies with the most deals in 2025 were dental companies. For a dental owner, most active capital is acquisition capital. Use those platforms as price evidence and as a fallback buyer, not as minority money.
Ownership data points the same way. PAI-Avalere data reported by Axia Growth shows 82.0% of physicians employed by hospitals or corporate entities as of January 1, 2026: 59.7% by hospitals and 22.3% by corporate entities such as PE firms or insurers. Hospitals and corporate entities owned 157,200 practices, 63.9% of the total, with corporate ownership (33.2%) ahead of hospital ownership (30.6%). Groups that want to stay independent need capital that does not take control. Family offices and physician investors fill that gap.
Observed data: hospital and health system M&A, 2025 through Q3 2026. Sources: Kaufman Hall Q3 2026 release, October 13, 2026, and quarterly and annual counts from Becker's Hospital Review reporting Kaufman Hall data.
| Measure (Kaufman Hall) | Figure |
|---|---|
| Transactions announced, Q1 / Q2 / Q3 2026 | 22 / 18 / 16 |
| Total through Q3 2026, against all of 2025 | 56, against 46 |
| 2025 count in context | Lowest annual count since tracking began in 2011 |
| Q3 2026 against Q3 2025 | Matched the same period last year |
| Total transacted revenue, Q3 2026 | $8.2 billion |
| Average seller size, Q3 2026 | About $586 million in annual revenue |
| Megamergers in Q3 2026 (more than $1 billion in annual revenue) | 2 |
| Share of Q3 2026 deals that were divestitures | Nearly one-third |
| Most common acquirer type, Q3 2026 | Not-for-profit organizations |
| Hospital operating margin with allocations, YTD through August 2026 | 2.5% |
| Hospitals operating at a loss, as of August 2026 | Nearly 43% |
| Non-labor expense per adjusted discharge, YTD through August 2026 vs 2025 | Up 6% (supply up 5%, drugs up 6%) |
Kaufman Hall tracks hospital M&A, not minority investing, so this data does not measure how often systems fund outside groups. It does show where their attention is. Margins are thin, costs are rising and systems are selling assets. For an independent owner, the practical opening is to buy a divested outpatient site with committed capital, not to pitch a system for a minority check.
4. Build the investor list: 4 tiers ranked by sector knowledge
| Tier | Who | Sector education needed | Typical ask | Decision process | Screen before pitching |
|---|---|---|---|---|---|
| 1 | Physicians and former operators in your specialty | Low | Minority stake, distributions, a board seat for a lead | Individual decision | Referral relationship with the company (Section 7) |
| 2 | Single family offices with healthcare wealth | Low to moderate | Minority or structured equity, governance rights | The principal, often with a small staff | Accredited status, conflicts with portfolio companies |
| 3 | Multi-family offices, independent sponsors, growth funds | Moderate | Preferred return, vetoes, a defined exit window | Investment committee, bound by fund life | Fund life, fee structure, restrictions from prior deals |
| 4 | PE platforms and strategics | Low on the sector, high on your numbers | Control or a path to control | Investment committee and a set process | Restrictions from prior deals in your specialty |
Start with Tiers 1 and 2. They already understand reimbursement, credentialing and payer mix, so their diligence goes to your numbers. Tier 1 also carries the most regulatory exposure, because the physicians who know your specialty best are often the ones who send you patients.
Model, not measured data: the investor funnel. A $6.0M raise with a $1.5M lead needs the lead plus three followers at $1.5M, or four at about $1.1M. That is four or five investors. We assume one in five first meetings produces an engaged investor, so five engaged investors takes 25 meetings. We assume 25% to 40% of names agree to a first meeting, so 25 meetings takes 63 to 100 names. A 60-name list at the same rates yields 15 to 24 meetings and three to five engaged investors, which leaves no margin if one drops. Build 80 to 100 names and replace these rates with your own once meetings start.
List-building checklist
- [ ] 80 to 100 names in Tiers 1 and 2 before any outreach
- [ ] Each name tagged by source of wealth, prior healthcare deals, typical check size and accredited status
- [ ] Each name flagged yes or no for referring patients to, or doing business with, the company
- [ ] Introduction path recorded for each name (lender, accountant, vendor, former partner)
- [ ] Each name tagged as a pre-existing relationship or a new contact, because securities rules treat outreach to strangers differently
- [ ] Private offering notices searched on SEC EDGAR full-text search for healthcare companies in your specialty and region. The notices name the issuer and its officers, not the investors, but they show who raised private capital and when, which points you to the backers
- [ ] Ten Tier 3 names held in reserve as a price check
- [ ] Two or three Tier 4 buyers identified as the walk-away alternative
- [ ] Reverse diligence on every lead investor, following Reverse Due Diligence
How Family Offices Invest in Healthcare explains how Tier 2 makes decisions.
5. Write the materials: a one-liner with numbers, a 12-slide deck and a 10-folder data room
A healthcare one-liner states EBITDA, site count, growth and the use of funds in one sentence. Expect to rewrite it several times.
Hypothetical one-liner. "Three-site dermatology group, $3.2M EBITDA, 18% same-site growth, raising $6M to open four de novo sites in a payer market we already contract with."
| Slide | Content | Number the investor looks for |
|---|---|---|
| 1 | One-liner and the raise | Amount, structure, use of funds |
| 2 | Business today | Sites, providers, revenue, adjusted EBITDA |
| 3 | Payer mix | Commercial, Medicare, Medicaid and self-pay shares |
| 4 | Provider base | Productivity per provider, retention, age profile |
| 5 | Growth record | Three-year revenue and EBITDA by site |
| 6 | Use of proceeds | Dollars by line, with payback per site |
| 7 | Market | Local share, referral sources, competing groups |
| 8 | Regulatory and structure | Entity chart, MSO structure, licenses |
| 9 | Management | Owners, administrators, compensation model |
| 10 | Projections | Base case and downside, three years |
| 11 | Terms | Valuation, security, governance, investor rights |
| 12 | Exit paths | Recap, platform sale, continued distributions |
Data room folders. Have these ready before the first meeting:
- Corporate and entity documents
- Three years of financials plus trailing twelve months
- EBITDA adjustment bridge
- Payer contracts and rate schedules
- Provider agreements and compensation plans
- Licenses, enrollment and accreditation
- Compliance program, audits and billing reviews
- Real estate and leases
- Litigation and claims
- Cap table, existing investor rights and prior securities filings
Build the folders from the Healthcare Data Room Checklist. Investors treat every gap as a reason to cut price. The EBITDA bridge is where you defend the valuation, so every add-back needs a document behind it.
Where investors cut price, and the document that stops it
| Investor's argument | Price effect | Document that answers it |
|---|---|---|
| "New sites are unproven" | Lower multiple on blended EBITDA | Site-level P&L with ramp curves by opening year |
| "Owner pay is below market" | Lower adjusted EBITDA | Market compensation survey, cross-checked against current wage data on the BLS Health Care and Social Assistance page, and a signed post-close pay plan |
| "Payer concentration" | Lower multiple | Payer contracts with renewal dates and rate history |
| "Provider departure risk" | Holdback or earnout | Employment agreements, tenure and productivity by provider |
| "Billing exposure" | Larger escrow | Third-party coding audit and remediation log |
6. Negotiate the terms a banker would: escrow, survival and rollover
Escrow and survival terms apply when an investor buys existing shares, as in a majority recap or partial sale. A primary minority round, where new money goes into the company, usually carries no escrow.
Observed data: SRS Acquiom, 2025 deals. Source: SRS Acquiom, 2026 Deal Terms for M&A Escrows. Population: 2025 deals in SRS Acquiom's dataset. Escrow is stated as a share of transaction value. "Not published" means the source gives no figure for that cell.
| Term | Without RWI | With RWI |
|---|---|---|
| Deals with an indemnification escrow or holdback | 84% | 92% |
| Sellers' general reps survive closing | 11% | 43% |
| Total escrow, average / median | 14.7% / 11.1% | Not published |
| General indemnification escrow, average / median | 11.3% / 10.0% | Not published |
RWI does not end seller exposure. In the same data, 92% of RWI deals still carried an indemnification escrow or holdback. The insurance changes who pays first and for how long.
Model, not a market quote: cash at close on a $20.0M majority recap without RWI. Our arithmetic. We assume 30% rollover and apply SRS Acquiom's total escrow median (11.1%) and average (14.7%). The base case sizes escrow on the full $20.0M headline price, which favors the buyer because part of that price is rollover the founder never receives in cash. The last rows size escrow on the cash portion only. All figures are before debt payoff, taxes and transaction fees. Escrow is deferred, not lost. It is released on schedule, less any claims.
| Line | Calculation | Amount |
|---|---|---|
| Headline price | $20.0M | |
| Rollover equity at 30% | $20.0M x 30% | $6.0M stays invested |
| Cash consideration | $20.0M minus $6.0M | $14.0M |
| Escrow at the 11.1% median, on $20.0M | $20.0M x 11.1% | $2.22M |
| Cash at close, median case | $14.0M minus $2.22M | $11.78M (58.9% of headline price) |
| Escrow at the 14.7% average, on $20.0M | $20.0M x 14.7% | $2.94M |
| Cash at close, average case | $14.0M minus $2.94M | $11.06M (55.3% of headline price) |
| Escrow on cash only, median / average | $14.0M x 11.1% / $14.0M x 14.7% | $1.55M / $2.06M |
| Cash at close, escrow on cash only, median / average | $14.0M minus $1.55M / minus $2.06M | $12.45M / $11.94M (62.2% / 59.7% of headline price) |
On these inputs the founder receives 55% to 59% of the headline price in cash at close when escrow is sized on the full price, and 60% to 62% when it is sized on cash only. Negotiating the escrow base is worth $0.67M to $0.88M at close. Model your own deal in the Deal Proceeds Calculator.
Term checklist for the owner
- [ ] Escrow percentage, the base it is sized on and release dates in writing at LOI
- [ ] Indemnity cap, basket and survival period set separately for general and fundamental reps
- [ ] RWI quote requested and premium split agreed
- [ ] Rollover equity valued at the same price per unit as the investor's cash
- [ ] Earnout tied to metrics the owner controls, with acceleration on a resale
- [ ] Minority protections: information rights, preemptive rights, tag-along, and a seat or observer right
- [ ] Liquidation preference and preferred return stated as numbers, so the effective minority discount is visible
- [ ] Non-compete scope and length agreed at LOI, not in the final documents
- [ ] Exit window, drag-along trigger and valuation method for any put or call
For a full recap, the Physician Practice Recapitalization white paper covers rollover terms and second-bite mechanics.
7. Deal breakers: what to settle before investors see a term sheet
Raises that stall after an LOI usually stall on an issue the owner could have raised in week three. The table lists the issues that most often reprice or delay a healthcare raise, the evidence that settles each early and where it sits in the 13-week plan.
| Issue | How it surfaces late | What to have ready | Plan week |
|---|---|---|---|
| Physician investors who also refer patients | Investor asks to restructure or remove their stakes | Referral-source flags from Section 4 and each physician's proposed stake | 3 |
| Where outside equity sits | Investor asks which entity it is actually buying into | Entity chart showing the practice, any MSO and the flow of management fees | 3 |
| How intermediaries are paid | A finder asks for a percentage of capital raised | Every intermediary, its role, whom it represents and how it is paid | 4 |
| Transaction review timing | The closing date moves | Every state where the company holds a license, plus expected deal size | 3 |
| Investor restrictions from earlier deals | An institutional investor cannot close in your specialty | Written answer from each institutional investor on restrictions in your specialty | 9 to 11 |
| Change of ownership in payer contracts and enrollment | Payer or enrollment steps delay cash after close | Payer contracts with change-of-control clauses flagged, current enrollment records | 5 |
| Tax structure of rollover and proceeds | After-tax value of competing offers shifts | Structure memo from the company's tax advisor before the LOI | 3 to 4 |
| Billing exposure | Investor asks for a larger escrow | Third-party coding audit and remediation log | 5 |
Model: what a late surprise costs. On the $20.0M recap in Section 6, a diligence finding that moves escrow from the 11.1% median to the 14.7% average cuts cash at close by $0.72M ($2.94M minus $2.22M). On the minority round in Section 2, a move from 8.0x to 6.5x hands the investor 4.6 more points of the company. Both costs shrink when the owner raises the issue first with the document already in the data room.
Regulatory areas that shape a healthcare raise
| Area | Why it can matter to this raise | Read more |
|---|---|---|
| Securities offering rules | Selling equity or notes is a securities offering. Most private raises rely on an exemption from SEC registration, and the exemption chosen governs how you may approach investors. Ask your attorney which one fits | SEC, exempt offerings |
| Broker-dealer registration and finder pay | Paying anyone a share of capital raised can raise registration issues. Ask your attorney before agreeing to pay any finder, broker or agent | FINRA BrokerCheck |
| Federal referral and self-referral rules | Returns paid to physicians who refer patients to the company can raise referral concerns. Ask your attorney which Tier 1 investors you can take and how their returns can be structured | HHS OIG, fraud and abuse laws |
| Corporate practice of medicine and MSO structure | State rules on who may own a medical practice vary and can shape which entity takes outside equity. Ask your attorney how they apply in your states | Management Services Organizations |
| State healthcare transaction notice laws | A growing number of states require notice or review before a healthcare deal closes, which can move the closing date | Healthcare M&A Process |
| Federal antitrust premerger notice and roll-up scrutiny | Larger deals can require a federal premerger filing, and serial acquisitions in one specialty can draw antitrust attention. Ask your attorney whether either applies | FTC, premerger notification |
| Medicare enrollment and change of ownership | A change in ownership can trigger enrollment steps that affect when the company is paid after close | Healthcare Compliance Due Diligence |
| Tax treatment | Rollover structure and entity type change the after-tax value of competing offers | Company tax advisor |
Have your attorney review each area that applies before the first investor outreach. The site's high-risk area guides on physician investors who refer, securities rules for raising capital and paying intermediaries set out the questions in more depth.
Week 3 advisor packet: eight items to hand over in one meeting
Advisors work faster and bill less when they get every input at once. Assemble this packet by the end of week 2, so the week 3 to 4 review produces one written memo, not a running email thread.
| Packet item | Where it comes from on this page | What it unblocks |
|---|---|---|
| Entity chart: the practice, any MSO, management fee flows | Section 7 table, slide 8 | Which entity the $6.0M goes into, and the terms slide |
| Cap table and existing investor rights | Data room folder 10 | The $21.6M pre-money at 8.0x and the 21.7% dilution math |
| Physician investor list with referral flags and proposed stakes | Section 4 checklist | Which Tier 1 names can be approached and on what terms |
| Full investor list tagged as pre-existing relationship or new contact | Section 4 checklist | How outreach in weeks 6 to 9 is run |
| Every intermediary: role, whom it represents, proposed pay, BrokerCheck record | Section 8 table | Engagement letters signed before any introductions |
| States where the company holds licenses, plus expected deal size | Section 7 table | A realistic closing date on the calendar |
| Payer contracts with change-of-control clauses flagged, enrollment records | Data room folders 4 and 6 | Cash flow timing after close |
| Draft deal figures: $6.0M minority raise at 8.0x, or $20.0M recap with 30% rollover | Sections 2 and 6 | Tax structure memo comparing after-tax proceeds |
A packet that is complete by week 3 also gives the owner the documents investors will ask for in weeks 9 to 11, so the work is done once.
8. Decide who represents you: advisors, finders and dual representation
Raising without a bank does not mean raising without advisors. It means knowing what each one is paid to do and whom each one works for.
| Role | Represents | Usual pay | Fits | Question to ask |
|---|---|---|---|---|
| Deal and healthcare regulatory counsel | The company | Hourly or fixed fee | Every raise | Which areas in Section 7 apply to us, and who prepares the filings? |
| QoE accountant | The company | Fixed fee | Raises large enough that investors commission their own QoE | Will the report hold up against the investor's QoE? |
| M&A broker | Seller or buyer | Success fee | Sale of control of a private company | Whom do you represent, in writing? |
| Placement agent | The issuer | Success fee plus expenses | Minority raises from passive investors | What registrations do you hold? Confirm on BrokerCheck |
| Finder | Unclear | Often asks for a percentage | Introductions | Whom do you represent, and exactly how are you paid? |
On a control sale, watch for dual representation. If an intermediary brings you a buyer it also advises, get written disclosure of whom it represents and give or withhold written consent before going further. Look up every placement agent, broker and individual banker on FINRA BrokerCheck for registration and disclosure history before signing an engagement letter. How to Choose a Healthcare Investment Banker covers engagement terms in more detail.
13-week action plan: 12 steps from model to signed term sheet
| Week | Step | Output | Owner |
|---|---|---|---|
| 1 | Define the use of funds and the amount | One-page use-of-proceeds table | CEO, CFO |
| 1 to 2 | Pick the capital layer | Debt, minority or control decision | CEO, board |
| 2 to 3 | Build the EBITDA bridge | Adjusted EBITDA with documentation | CFO, QoE firm |
| 3 | Price the business | Control reference, minority range and sensitivity table from Section 2 | CFO |
| 3 to 4 | Legal, regulatory and tax review | One written memo covering the Section 7 areas and the advisor packet, securities approach settled, physician investors reviewed | Deal counsel, tax advisor |
| 4 | Write and rewrite the one-liner | Final one-liner with numbers | CEO |
| 4 to 5 | Build the 12-slide deck | Deck and three-year model | CEO, CFO |
| 5 | Stand up the data room | Ten folders, index and access log | Administrator |
| 5 to 6 | Build the investor list | 80 to 100 Tier 1 and 2 names, ranked and flagged | CEO |
| 6 to 9 | Outreach and first meetings | Planning target of 25 meetings, notes logged | CEO |
| 9 to 11 | Second meetings, reverse diligence | Engaged investors vetted, restrictions from prior deals confirmed in writing | CEO, CFO |
| 11 to 13 | Negotiate terms and sign | Term sheet with valuation, governance and exit terms set, filings calendared | CEO, deal counsel |
How we calculated the derived figures
| Figure on this page | Inputs and source | Our assumption |
|---|---|---|
| Growth investments 20.8%, add-ons 64.5%, buyouts 14.7% | 214, 664 and 151 of 1,029 PE healthcare deals (PESP, 2025) | None |
| Outpatient add-ons 80.4% | 119 of 148 outpatient deals (Becker's ASC Review, PESP data, 2025) | None |
| Debt example: 1.9x new debt, 3.1x total, 1.3x unchanged, $0.9M interest, 28% of EBITDA | $3.2M EBITDA, $4.0M existing net debt, $6.0M raise | Hypothetical group, full $6.0M borrowed and added to existing debt, 9% all-in rate on all $10.0M |
| Minority pricing: 21.7% at 8.0x, 18.5% at 9.5x | $3.2M EBITDA, $4.0M net debt, $6.0M raise | 9.5x control point inside Sikich's 9 to 11x band, 8.0x minority multiple, gross of fees, no other dilution |
| Sensitivity table, 6.5x to 9.5x | Same group | Each multiple is an input, not a benchmark |
| Funnel: 25 meetings, 63 to 100 names | Four or five investors needed | 25% to 40% meeting rate, one in five meetings converts |
| Cash at close, 55% to 62% of headline price | SRS Acquiom 2025 total escrow without RWI, 11.1% median and 14.7% average | $20.0M price, 30% rollover, before debt payoff, taxes and fees |
| Escrow base worth $0.67M to $0.88M | $2.22M minus $1.55M, $2.94M minus $2.06M | Same recap |
| Late-surprise escrow cost, $0.72M | $2.94M minus $2.22M | Same recap, escrow on the full price |
Questions owners ask
Can a healthcare company raise capital without hiring an investment bank?
Yes. The owner does the five jobs a banker does: price the business from private-deal data, choose the capital layer, build a ranked investor list, produce the materials and negotiate the terms. The company avoids an investment bank's success fee and deals with its investors directly. If it later hires a placement agent or broker, that intermediary is usually paid on success, so the saving depends on how the raise is staffed.
What multiple should I expect when selling equity in a physician practice?
Size sets most of the price. Sikich's Q3 2026 update gives indicative physician-practice ranges of 5 to 7x EBITDA below $1 million of EBITDA and 11 to 13x above $5 million. Axia Growth's closed healthcare sales data (as of October 28, 2026) shows a 5.1x median at $2 million to $3 million of EBITDA (13 sales) and 12.9x at $10 million and up (17 sales). These are control prices. A minority investor pays a lower multiple for the same EBITDA or makes up the difference through preferences and governance rights. None of these datasets publishes a standard minority discount, so negotiate it as a stated number.
Which investors should a healthcare owner approach first?
Start with investors who already understand healthcare: physicians, former operators and family offices whose wealth came from the sector. Their diligence goes to your numbers, not to basic education on reimbursement. Flag every physician investor who refers patients to the company. Federal referral and self-referral rules can restrict how referring physicians invest and how their returns are paid, so ask your attorney how to structure those stakes before offering them. Raising Capital from Physician Investors covers the questions. PE platforms generally want control. Hospital finances are thin. Kaufman Hall reports a 2.5% year-to-date hospital operating margin, including allocations, through August 2026, with nearly 43% of hospitals operating at a loss.
How much of my sale price will sit in escrow?
In SRS Acquiom's 2025 deal data, total escrow on deals without representation and warranty insurance (RWI) averaged 14.7% of transaction value, with a median of 11.1%. The general indemnification escrow alone averaged 11.3% (median 10.0%). On a hypothetical $20 million recap with escrow sized on the full price, our arithmetic puts total escrow at $2.22 million at the median and $2.94 million at the average. Insurance does not remove escrow. In the same data, 92% of deals with RWI still carried an indemnification escrow or holdback.
Do I have to file anything with the SEC for a private healthcare raise?
Usually, yes. Selling equity or notes to investors is a securities offering. Most private raises rely on an exemption from SEC registration and involve a short notice filing that anyone can search on SEC EDGAR. The exemption you choose also governs how you may approach investors, so settle it with your attorney before the first outreach. Capital Raising for Healthcare Companies covers the questions.
Can I pay someone a percentage for introducing investors?
Not without checking first. Paying a percentage of capital raised is transaction-based pay, which is the activity broker-dealer registration rules are built around. Confirm the person's registration on FINRA BrokerCheck, put the role and the pay in a written engagement letter and sign it before any introduction is made. How to Choose a Healthcare Investment Banker covers the issues.
Sources
- Private Equity Stakeholder Project, Private Equity Healthcare Deals: 2025 in Review (PitchBook and LevinPro HC data)
- Becker's ASC Review, outpatient specialties in 2025 deal activity (PESP data)
- Becker's Hospital Review, Kaufman Hall hospital M&A data through Q3 2026
- Kaufman Hall, Q3 2026 M&A Quarterly Activity Report press release, October 13, 2026
- Buckhead FMV, Healthcare Services M&A Valuation Multiples, control transactions January 2023 to October 2026
- Sikich, Q3 2026 US Healthcare M&A Market Update and Year-End Outlook (includes PitchBook data)
- Axia Growth, closed healthcare small-business sales data and PAI-Avalere ownership data, as of October 28, 2026
- Aswath Damodaran, NYU Stern, EV/EBITDA multiples by sector (US), January 2026
- Aswath Damodaran, NYU Stern, Price and EV to Sales by industry (US), January 2026
- SRS Acquiom, 2026 Deal Terms for M&A Escrows, 2025 deal data
- CMS, National Health Expenditure fact sheet, 2024 data and 2025 to 2034 projections
- U.S. Small Business Administration, 7(a) loans
- FTC, a 2025 consent order on healthcare roll-up acquisitions
- FTC, Premerger Notification Program
- HHS OIG, fraud and abuse laws
- SEC, exempt offerings
- SEC EDGAR full-text search
- FINRA BrokerCheck
- U.S. Bureau of Labor Statistics, Health Care and Social Assistance industry page